NCT03277924 2024-08-13ImmunoSarcGrupo Espanol de Investigacion en SarcomasPhase 1/2 Completed197 enrolled
NCT04593758 2023-05-24To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft TissueCornerstone PharmaceuticalsPhase 1/2 Completed16 enrolled